personalized, neoantigen-directed immunotherapy in patients with advanced mss-crc, gea and nsclc
Published 2 years ago • 243 plays • Length 4:11Download video MP4
Download video MP3
Similar videos
-
0:46
key limitations of current treatment options for patients with mss-crc
-
6:56
prior rt may potentially enhance treatment of mss-crc with regorafenib and pembrolizumab
-
0:41
how can immunotherapies successfully target mss colorectal cancer?
-
25:23
targeting tumor mutations for personalized cancer immunotherapy
-
1:26
the future of personalized, neoantigen cancer vaccines
-
5:48
emerging immunotherapy combinations in mss crc
-
1:09
dr. mccollum on immunotherapy in mss crc
-
6:11
immunotherapy in crc
-
1:08
the role of neoadjuvant immunotherapy in msi-high gastric cancer
-
0:50
emerging role of adjuvant immunotherapy in oncology
-
1:25
neoadjuvant immunotherapy in msi-high colorectal cancer
-
1:19
pemrec: neo-adjuvant pembrolizumab and rt in rectal cancer
-
0:49
st101: targeting c/ebpβ in patients with advanced solid tumors
-
3:27
crc: emerging immunotherapy strategies in mss tumors
-
0:58
dr. morris on the role of immunotherapy in metastatic crc
-
2:30
targeting public neoantigens in cancer immunotherapies
-
2:21
phase 2 expansion cohorts for its personalized neoantigen immunotherapy granite
-
3:29
lenvatinib and pembrolizumab in microsatellite stable crc